Nezulcitinib (TD-0903) Dose A
0196
Phase 1 small_molecule completed
Quick answer
Nezulcitinib (TD-0903) Dose A for Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Theravance Biopharma
- Indication
- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed